Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clin... ( BOSTON Jan. 29 /- Surface Logix t...)

Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial

Date:1/29/2008

BOSTON, Jan. 29 /PRNewswire/ -- Surface Logix today announced positive results in the Company's Phase 2a clinical trial of SLx-4090 in dyslipidemia (high cholesterol and triglyceride levels in the bloodstream). The randomized, double-blind, placebo-controlled Phase 2a study in 24 patients with dyslipidemia demonstrated that SLx-4090 caused clinically significant reductions in postprandial triglycerides and LDL-cholesterol and was well tolerated. The trial was designed to examine the safety, tolerability, pharmacokinetics and effect on lipid profiles in patients administered repeat oral doses of SLx-4090 either three times daily or once daily for 14 days. The Company intends to initiate a Phase 2b study of SLx-4090 in dyslipidemia in the third quarter of 2008.

"The Phase 2a trial showed that SLx-4090 was efficacious and well tolerated in patients," said Dr. Warwick Tong, Senior Vice President of Commercial Development of Surface Logix. "We were particularly pleased to see, in both dosing regimens, drops not only in postprandial triglycerides but also in fasting LDL-cholesterol levels in just 14 days. Importantly, SLx-4090's adverse event profile was indistinguishable from that of placebo. We saw no effect on liver function tests, which is consistent with the compound being undetectable in the plasma, and no impact on bowel habit."

"We were also pleased to see clinically significant weight loss in patients who received SLx-4090," added Dr. William Prince, Chief Development Officer of Surface Logix. "We attribute this to the decreased uptake of triglycerides, a significant source of calories in the diet. Given that obesity is a major and growing health concern, we believe SLx-4090's potential to cause weight loss represents a significant opportunity for therapeutic intervention."

SLx-4090 is a novel, oral, non-systemically available inhibitor of microsomal triglyceride transfer protein (MTP) that acts by blocking the formation of particles k
'/>"/>

1

GOOD

Page: 1 2 3 4
Related biology technology :

1. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
2. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
3. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
4. Physicists pin down spin of surface atoms
5. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
6. NanoLogix, Inc. Makes Stock Pick List
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
9. ForceLogix, Innovex Win Sales Operational Performance Award
10. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
11. Resverlogix is Presenting at IAS HDL Workshop

Post Your Comments:

Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clin...( BOSTON Jan. 29 /- Surface Logix t...)